Advanced Ovarian Cancer Care and Treatment Experiences (ADVOCATE)
Principal Investigator: Dr Val Jenkins
Statistician: Dr Ivonne Solis-Trapala
Funded by an educational grant from Industry and sponsored by BSMS.
Background: Up to 75% of women with ovarian cancer have non-localised disease at the time of diagnosis. Therapy for advanced disease is palliative and aims to reduce symptoms without introducing extra burdens and iatrogenic harms. Maintenance therapy is not yet standard care, but may benefit patients in terms of symptom palliation, quality of life and survival, particularly if combined with appropriate supportive care; however this remains under-researched and under-reported. Furthermore, patient preferences for treatment options have not been studied sufficiently or systematically.
Aims: To conduct an observational study in patients with advanced ovarian cancer to examine experience of and preferences for treatment and care. Identifying:
- the most bothersome symptoms and side- effects and how well these are monitored and ameliorated.
- the types and amounts of information patients require about the disease and treatment options
- patient preferences for follow- up (i.e. contact frequency, by whom)
Participants (target 200 patients):
- >18yrs with advanced (Stage II-IV) ovarian cancer and not currently an inpatient
- receiving, or recently completed 1st- line, subsequent/maintenance chemotherapy
- able to read & speak English and provide informed consent.
Methods: Eligible patients will be indentified by their healthcare team and offered a study invitation pack during clinic attendance. Those willing to participate will return an expression of interest form and will then be contacted by the researchers. Following informed consent a one-off semi-structured interview will be conducted either by phone or via a home visit depending on participant preference. This interview will take about 30 minutes and gathers information on: demography, diagnosis, treatments received, symptoms and side-effects experienced, preferences for ongoing treatment and supportive care, and information needs. Additionally, patients will be asked to complete 2 standard questionnaires (EORTC QLQC30- OV28; EORTC-Info25)